Oriheal Pimotone 10mg (Pimobendan) Tablet for Dogs and Cats
Inclusive of all taxes
Product Details
| Product type | Oral Tablets |
| Volume / Quantity | Pack of 30 Tablets (Typically packaged as 3 strips of 10 tablets or 30 tablets in 1 bottle) |
| Target Species | Canines and Felines (Dogs and cats diagnosed with advanced cardiovascular disease or cardiac enlargement) |
| Common Use Case | Long-term therapeutic management of clinical congestive heart failure (CHF) stemming from Myxomatous Mitral Valve Disease (MMVD) or Dilated Cardiomyopathy (DCM); reduction of peripheral blood vessel congestion; delaying heart failure progression in pre-clinical DCM or mitral valve disease; and improving blood volume output to alleviate fatigue, chronic coughing, and exercise intolerance. |
Oriheal Pimotone 10mg is a high-potency, prescription-only veterinary cardiovascular medication formulated for the clinical management and treatment of advanced congestive heart failure (CHF) and structural heart disease in dogs and cats. The active pharmaceutical ingredient, Pimobendan (10mg), is a premier "inodilator" that operates via a crucial dual mechanism of action: it acts as a calcium sensitizer to directly enhance myocardial contractility (positive inotropy) while simultaneously functioning as a phosphodiesterase III (PDE3) inhibitor to dilate peripheral and systemic blood vessels.
This targeted, high-strength formulation minimizes resistance in systemic blood pathways, decreases the preload and afterload on weak heart chambers, and optimizes total cardiac output without increasing myocardial oxygen consumption. In canine patients, Pimotone 10mg is a mainstay treatment for large or giant breeds suffering from congestive heart failure secondary to Dilated Cardiomyopathy (DCM) or Atrio-Ventricular Valvular Insufficiency (AVVI/MMVD). It is also prescribed in pre-clinical stages to delay the onset of clinical heart failure in cases with confirmed cardiac enlargement. In feline healthcare, it serves under strict veterinary discretion for advanced myocardial pathologies showing systolic dysfunction. Formulated as a palatable chewable tablet, it noticeably reduces severe clinical symptoms such as chronic coughing, breathlessness, and extreme lethargy, significantly enhancing the animal's daily quality of life and long-term survival time.
